Entropy Neurodynamics Reports Encouraging First-Patient Data for IV Psilocin in Binge Eating Disorder Trial

Tryptamine Therapeutics ( (AU:ENP) ) has issued an update.

Entropy Neurodynamics reported that the first Binge Eating Disorder patient treated with its IV psilocin candidate TRP-8803 in combination with psychotherapy has completed a four-week follow-up, showing clinically meaningful improvements across binge severity, mood, anxiety, body image satisfaction and overall wellbeing. Clinicians and management say the early, multi-domain benefits exceed expectations and support TRP-8803’s potential to offer a more controlled and scalable psychedelic-assisted therapy than oral psilocybin, with upcoming dosing of additional patients and higher-dose cohorts in early 2026 expected to guide further trial design, regulatory engagement and expansion into broader eating disorder and neuropsychiatric indications.

The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.

More about Tryptamine Therapeutics

Entropy Neurodynamics Limited is a clinical-stage biotechnology company developing psychedelic-assisted therapies, with a focus on its proprietary intravenously infused psilocin formulation, TRP-8803. The company is targeting neuropsychiatric indications, including eating disorders such as Binge Eating Disorder (BED), by offering more precise, controllable alternatives to traditional oral psilocybin treatments.

Average Trading Volume: 2,293,747

Technical Sentiment Signal: Sell

Current Market Cap: A$54.79M

For detailed information about ENP stock, go to TipRanks’ Stock Analysis page.